NASDAQ:CELG - Celgene Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$88.15 -1.48 (-1.65 %)
(As of 03/22/2019 04:00 PM ET)
Previous Close$88.15
Today's Range$87.96 - $89.50
52-Week Range$58.59 - $95.30
Volume7.31 million shs
Average Volume10.23 million shs
Market Capitalization$61.91 billion
P/E Ratio11.58
Dividend YieldN/A
Beta1.69
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include IDHIFA, a small molecule inhibitor of the isocitrate dehydrogenase 2 to treat acute myeloid leukemia (AML); VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; and THALOMID to treat patients with MM and erythema nodosum leprosum. Its clinical stage products comprise OTEZLA to treat various immune-inflammatory diseases; luspatercept for the treatment of patients with beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; CC-92480 to treat multiple myeloma; and durvalumab, an anti-PD-L1 antibody for hematological cancers. The company has agreements with BeiGene, Ltd; Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; Vividion Therapeutics, Inc.; Jounce Therapeutics, Inc.; Prothena Corporation plc; Zymeworks Inc.; and Evotec AG, as well as strategic collaborations with Skyhawk Therapeutics, Inc., Dragonfly Therapeutics, Inc., Obsidian Therapeutics, Philogen S.p.A., and Kyn Therapeutics. The company was founded in 1980 and is headquartered in Summit, New Jersey.

Receive CELG News and Ratings via Email

Sign-up to receive the latest news and ratings for CELG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CELG
CUSIP15102010
Phone908-673-9000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$15.28 billion
Cash Flow$8.7277 per share
Book Value$8.79 per share

Profitability

Net Income$4.05 billion

Miscellaneous

Employees8,852
Market Cap$61.91 billion
Next Earnings Date5/3/2019 (Estimated)
OptionableOptionable

Celgene (NASDAQ:CELG) Frequently Asked Questions

What is Celgene's stock symbol?

Celgene trades on the NASDAQ under the ticker symbol "CELG."

When did Celgene's stock split? How did Celgene's stock split work?

Shares of Celgene split on the morning of Thursday, June 26th 2014. The 2-1 split was announced on Thursday, June 19th 2014. The newly minted shares were distributed to shareholders after the closing bell on Wednesday, June 25th 2014. An investor that had 100 shares of Celgene stock prior to the split would have 200 shares after the split.

How will Celgene's stock buyback program work?

Celgene declared that its Board of Directors has approved a share buyback plan on Thursday, May 24th 2018, which permits the company to repurchase $3,000,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to buy up to 5.4% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company's management believes its stock is undervalued.

How were Celgene's earnings last quarter?

Celgene Co. (NASDAQ:CELG) issued its quarterly earnings results on Thursday, January, 31st. The biopharmaceutical company reported $2.39 earnings per share for the quarter, beating the consensus estimate of $2.32 by $0.07. The biopharmaceutical company had revenue of $4.04 billion for the quarter, compared to the consensus estimate of $3.98 billion. Celgene had a net margin of 26.48% and a return on equity of 114.66%. During the same period in the previous year, the business posted $2.00 earnings per share. View Celgene's Earnings History.

When is Celgene's next earnings date?

Celgene is scheduled to release their next quarterly earnings announcement on Friday, May 3rd 2019. View Earnings Estimates for Celgene.

What guidance has Celgene issued on next quarter's earnings?

Celgene issued an update on its FY19 earnings guidance on Thursday, January, 31st. The company provided EPS guidance of $10.60-10.80 for the period, compared to the Thomson Reuters consensus EPS estimate of $10.66. The company issued revenue guidance of $17-17.2 billion, compared to the consensus revenue estimate of $17.11 billion.Celgene also updated its FY 2019 guidance to $10.60-10.80 EPS.

What price target have analysts set for CELG?

23 brokers have issued 1 year target prices for Celgene's stock. Their forecasts range from $77.00 to $129.00. On average, they expect Celgene's share price to reach $100.50 in the next twelve months. This suggests a possible upside of 14.0% from the stock's current price. View Analyst Price Targets for Celgene.

What is the consensus analysts' recommendation for Celgene?

23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celgene in the last year. There are currently 11 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Celgene.

What are Wall Street analysts saying about Celgene stock?

Here are some recent quotes from research analysts about Celgene stock:
  • 1. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and $100 12-month price target. Celgene reported a strong 4Q this morning and issued full year 2019 guidance. 4Q revs of ~$4B beat us and consensus on the top line, while adj. EPS of $2.39 also came in above us and consensus at $2.33 and $2.32. Base business trends were surprisingly strong, and management reiterated timelines for all five late- stage pipeline products on track for approval by the end of 2020. We think the key takeaway from the call was that commercial and pipeline execution appear to be back on track with a clear line of sight to the Bristol (BMY, NC) deal closing in 3Q19. We think guidance for 2019 seems conservative." (1/31/2019)
  • 2. According to Zacks Investment Research, "Celgene recently announced a merger agreement with Bristol-Myers Squibb Company. Per the terms, Celgene shareholders will receive 1.0 share of Bristol-Myers and $50.00 in cash for each share held. The total consideration represents an approximately 51% premium to Celgene shareholders based on the 30-day volume weighted average closing stock price prior to signing. Celgene gets a reprieve from the acquisition, having faced a series of pipeline setbacks in recent times. Lead drug Revlimid, continues to drive revenues. Celgene is also working on label expansion of drugs like Pomalyst/Imnovid, Abraxane and Otezla among others, which is encouraging. Meanwhile, the company is focused on the next cycle of innovation with five late-stage candidates — ozanimod, fedratinib, luspatercept, liso-cel and bb2121 — all of which are expected to be launched by the end of 2020. Shares have outperformed the industry in the last six months." (1/23/2019)
  • 3. Mizuho analysts commented, "We updated our model post the 2Q18 earnings call. Here are the key changes we made: ===Upward Revisions=== 1. bb2121. Added bb2121 to pipeline section of the model ($1Bn in risk- adjusted peak sales to CELG vs consensus of $900MM) 2. Luspatercept. Increased POS from 67% to 90% on the back of the recent positive Ph 3 results. (peak risk-adj sales now of $1Bn, ex-royalty to XLRN …. consensus at $850MM) ===Downward Revisions=== 3. Ozanimod MS. Trimmed peak risked adjusted sales from $1.3Bn to $1.1Bn. In total, across all 3 indications (MS, UC, CD), we carry $2.8Bn (vs consensus of $2.5Bn)." (7/31/2018)
  • 4. Cowen Inc analysts commented, "We will be hosting a conference call with neurologist to discuss and TD-9855. Theravance is evaluating 1/2 trial in patients with . Results are expected to be available this month." (7/10/2018)

Has Celgene been receiving favorable news coverage?

News headlines about CELG stock have been trending somewhat positive on Saturday, according to InfoTrie Sentiment. The research firm scores the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Celgene earned a media sentiment score of 0.6 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future.

Are investors shorting Celgene?

Celgene saw a increase in short interest in February. As of February 28th, there was short interest totalling 19,130,340 shares, an increase of 11.8% from the February 15th total of 17,114,939 shares. Based on an average daily trading volume, of 11,821,409 shares, the days-to-cover ratio is presently 1.6 days. Approximately 2.7% of the company's stock are short sold. View Celgene's Current Options Chain.

Who are some of Celgene's key competitors?

What other stocks do shareholders of Celgene own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Celgene investors own include Gilead Sciences (GILD), Alibaba Group (BABA), NVIDIA (NVDA), Netflix (NFLX), Micron Technology (MU), Bank of America (BAC), Intel (INTC), Walt Disney (DIS), Visa (v) and Starbucks (SBUX).

Who are Celgene's key executives?

Celgene's management team includes the folowing people:
  • Mr. Mark J. Alles, Chairman & CEO (Age 60)
  • Mr. Peter N. Kellogg, Exec. VP & Chief Corp. Strategy Officer (Age 63)
  • Dr. S. J. Rupert Vessey, Pres of Research & Early Devel. (Age 54)
  • Mr. David V. Elkins, Exec. VP & CFO
  • Mr. Aijaz Tobaccowalla, Sr. VP and Chief Digital & Information Officer (Age 52)

Who are Celgene's major shareholders?

Celgene's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.65%), Oregon Public Employees Retirement Fund (2.36%), Geode Capital Management LLC (1.42%), Northern Trust Corp (1.29%), FMR LLC (1.26%) and Norges Bank (1.08%). Company insiders that own Celgene stock include Ernest Mario, Gilla Kaplan, James J Loughlin, John H Weiland, Mark J Alles, Michael A Friedman, Michael D Casey, Robert J Hugin, Rupert Vessey and Terrie Curran. View Institutional Ownership Trends for Celgene.

Which major investors are selling Celgene stock?

CELG stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Carmignac Gestion, FMR LLC, Thrivent Financial for Lutherans, BB Biotech AG, Canada Pension Plan Investment Board, Stifel Financial Corp and Mackenzie Financial Corp. Company insiders that have sold Celgene company stock in the last year include Ernest Mario, Gilla Kaplan, James J Loughlin and Michael D Casey. View Insider Buying and Selling for Celgene.

Which major investors are buying Celgene stock?

CELG stock was acquired by a variety of institutional investors in the last quarter, including Oregon Public Employees Retirement Fund, Norges Bank, Parnassus Investments CA, BlackRock Inc., Candriam Luxembourg S.C.A., Geode Capital Management LLC, Worldquant Millennium Quantitative Strategies LLC and Two Sigma Advisers LP. Company insiders that have bought Celgene stock in the last two years include Ernest Mario, John H Weiland and Mark J Alles. View Insider Buying and Selling for Celgene.

How do I buy shares of Celgene?

Shares of CELG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Celgene's stock price today?

One share of CELG stock can currently be purchased for approximately $88.15.

How big of a company is Celgene?

Celgene has a market capitalization of $61.91 billion and generates $15.28 billion in revenue each year. The biopharmaceutical company earns $4.05 billion in net income (profit) each year or $7.61 on an earnings per share basis. Celgene employs 8,852 workers across the globe.

What is Celgene's official website?

The official website for Celgene is http://www.celgene.com.

How can I contact Celgene?

Celgene's mailing address is 86 MORRIS AVENUE, SUMMIT NJ, 07901. The biopharmaceutical company can be reached via phone at 908-673-9000 or via email at [email protected]


MarketBeat Community Rating for Celgene (NASDAQ CELG)

Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  1,946 (Vote Outperform)
Underperform Votes:  704 (Vote Underperform)
Total Votes:  2,650
MarketBeat's community ratings are surveys of what our community members think about Celgene and other stocks. Vote "Outperform" if you believe CELG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CELG will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel